Scarica l'app Stockscreener
558.60
0.53%
2.93
Dopo l'orario di chiusura:
558.24
-0.36
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IDXX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$555.67
Aprire:
$552.47
Volume 24 ore:
807.18K
Relative Volume:
1.29
Capitalizzazione di mercato:
$44.06B
Reddito:
$4.45B
Utile/perdita netta:
$1.10B
Rapporto P/E:
41.10
EPS:
13.591
Flusso di cassa netto:
$1.06B
1 W Prestazione:
+0.14%
1M Prestazione:
-3.50%
6M Prestazione:
-21.69%
1 anno Prestazione:
+3.32%
Intervallo 1D:
$547.38
$562.02
Intervallo di 1 settimana:
$547.38
$577.15
Portata 52W:
$506.91
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Nome
Idexx Laboratories Inc
Settore
Industria
Telefono
(207) 556-0300
Indirizzo
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
558.60 | 43.83B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
524.71 | 189.58B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
195.98 | 135.02B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
281.85 | 39.30B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
133.59 | 36.45B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Citigroup | Neutral |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-31 | Aggiornamento | Stifel | Hold → Buy |
| 2025-10-01 | Iniziato | UBS | Neutral |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-01 | Iniziato | Jefferies | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | BTIG Research | Buy |
| 2024-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-12-04 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Downgrade | Stifel | Buy → Hold |
| 2022-07-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-07-12 | Iniziato | Piper Sandler | Overweight |
| 2022-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-08 | Iniziato | Atlantic Equities | Overweight |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-17 | Iniziato | Barclays | Overweight |
| 2019-09-09 | Iniziato | Goldman | Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Buy |
| 2018-11-02 | Reiterato | BofA/Merrill | Buy |
| 2018-05-07 | Reiterato | Stifel | Buy |
| 2018-01-16 | Iniziato | Piper Jaffray | Overweight |
| 2017-08-23 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Aggiornamento | CL King | Neutral → Buy |
| 2017-02-03 | Downgrade | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Ripresa | BofA/Merrill | Neutral |
| 2016-08-16 | Reiterato | Stifel | Buy |
| 2016-08-03 | Aggiornamento | Northcoast | Sell → Neutral |
| 2016-07-20 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-19 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-01 | Iniziato | CL King | Neutral |
| 2016-03-21 | Reiterato | Stifel | Buy |
| 2016-02-04 | Iniziato | Credit Suisse | Outperform |
| 2015-10-29 | Reiterato | Stifel | Buy |
| 2015-08-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Reiterato | Stifel | Buy |
| 2015-07-23 | Reiterato | Canaccord Genuity | Buy |
Mostra tutto
Idexx Laboratories Inc Borsa (IDXX) Ultime notizie
IDEXX Laboratories focuses on diagnostics growth. Investors watch demand trends - Ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories extends its diagnostics reach as a key S&P 500 health-tech name - Ad-hoc-news.de
IDEXX Laboratories Does Not Need More Vet Visits, But It Needs More Tests Per Visit (IDXX) - Seeking Alpha
IDEXX Laboratories focuses on diagnostics growth. Business model supports long-term demand - Ad-hoc-news.de
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices - TIKR.com
IDEXX Laboratories stock holds its focus on diagnostics. Investors watch the business mix. - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a Potential 27% Upside for Investors - DirectorsTalk Interviews
IDEXX Laboratories stock tracks its core diagnostics business - AD HOC NEWS
IDXXIdexx Laboratories Inc Volatility & Greeks - Finviz
Enterprise value to EBIT forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories stock leans on its diagnostics base - Ad-hoc-news.de
Price to sales forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist? - Moomoo
EULAV Asset Management's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories Inc (IDXX) Stock Up 3.8% and Still Undervalued -- GF Score: 96/100 - GuruFocus
IDEXX Laboratories to Release 2026 Second Quarter Financial Results - 01net
Press Release: IDEXX Laboratories to Release 2026 Second Quarter Financial Results - 富途牛牛
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell Midcap Value Benchmark - marketscreener.com
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock? - Zacks Investment Research
Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN
IDEXX Laboratories (IDXX) Stock Analysis: Uncovering a Potential 28.58% Upside for Investors - DirectorsTalk Interviews
IDEXX Laboratories with a clear strategy focus, shares anchored in the NASDAQ-100 - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value Benchmark - marketscreener.com
The Catalyst Dx from IDEXX Laboratories Inc.compact chemistry analyzer for fast in-clinic results - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value-Defensive Index - marketscreener.com
IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend - Ad-hoc-news.de
IDEXX Laboratories focuses on long-term growth, shares in NASDAQ-100 healthcare peer group - Ad-hoc-news.de
New diagnostic test for kidney injury - DVM360
IDEXX Laboratories opens the week with earnings focus, shares steady - Ad-hoc-news.de
IDEXX Laboratories, Inc. Actuals & Estimates (NASDAQ:IDXX) - TradingView
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX) - TradingView
IDXX Forecast — Price Target — Prediction for 2027 - TradingView
IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock - Ad-hoc-news.de
Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1 - TradingView
Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15 - TIKR.com
Are IDEXX Laboratories’ (IDXX) New SDMA and Tapeworm Tests Deepening Its Diagnostics Moat? - Sahm
IDEXX Laboratories Inc (IDXX) Institutional Confidence - TradingKey
Price to book forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Enterprise value to revenue forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories analyst consensus stays firm, shares trade below recent high - Ad-hoc-news.de
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SNAP 4Dx Plus Test from IDEXX Laboratoriesquick tick-borne screening in minutes - Ad-hoc-news.de
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. - marketscreener.com
A Small Upgrade Could Have a Big Impact for IDEXX Customers - Insider Monkey
IDEXX Laboratories StockSaturday deep dive into the long-term business model - Ad-hoc-news.de
IDEXX Laboratories Sharesanalyst consensus stays cautious - Ad-hoc-news.de
IDEXX Laboratories Stock Is Down 16% in 2026: Does the Q1 Beat Make It a Buy at $562? - TIKR.com
Idexx Laboratories Inc Azioni (IDXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):